MA41326A - Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation - Google Patents

Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation

Info

Publication number
MA41326A
MA41326A MA041326A MA41326A MA41326A MA 41326 A MA41326 A MA 41326A MA 041326 A MA041326 A MA 041326A MA 41326 A MA41326 A MA 41326A MA 41326 A MA41326 A MA 41326A
Authority
MA
Morocco
Prior art keywords
preparation
high purity
pharmaceutical formulations
including high
formulations including
Prior art date
Application number
MA041326A
Other languages
English (en)
Inventor
Min Ding
Panna Dutta
Rajeshwar Motheram
Far Adel Rafai
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55537309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41326(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA41326A publication Critical patent/MA41326A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
    • B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
    • B65D81/2069—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas in a special atmosphere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041326A 2015-01-14 2015-07-10 Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation MA41326A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562103136P 2015-01-14 2015-01-14

Publications (1)

Publication Number Publication Date
MA41326A true MA41326A (fr) 2021-04-28

Family

ID=55537309

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041326A MA41326A (fr) 2015-01-14 2015-07-10 Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation

Country Status (13)

Country Link
US (4) US9295687B1 (fr)
EP (1) EP3244900A4 (fr)
KR (1) KR102440847B1 (fr)
CN (2) CN115990138A (fr)
BR (1) BR112017014996A2 (fr)
CA (1) CA2971868C (fr)
CL (1) CL2017001840A1 (fr)
CO (1) CO2017006958A2 (fr)
MA (1) MA41326A (fr)
MX (1) MX2017009289A (fr)
PE (2) PE20171246A1 (fr)
RU (1) RU2733409C2 (fr)
WO (1) WO2016114818A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109406A1 (fr) * 2011-02-09 2012-08-16 The Medicines Company Méthodes de traitement de l'hypertension pulmonaire
MA41326A (fr) * 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
WO2018234565A1 (fr) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法
CN109781920B (zh) * 2017-11-15 2023-07-11 石药集团中奇制药技术（石家庄）有限公司 一种坎格雷洛有关物质的hplc检测方法
CN109912674A (zh) 2017-12-12 2019-06-21 亚宝药业集团股份有限公司 一种坎格雷洛四钠盐的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679721B2 (en) 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
US5684008A (en) * 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
GB9813646D0 (en) * 1998-06-24 1998-08-26 Ciba Geigy Ag Organic compounds
SE9903345D0 (sv) 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
KR100962105B1 (ko) 2001-09-21 2010-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 동결 건조 제제
SG161101A1 (en) 2002-02-22 2010-05-27 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same
WO2009140092A1 (fr) 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8680052B1 (en) * 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20120184504A1 (en) * 2009-10-02 2012-07-19 Strony John T "The Use of a PAR-1 Antagonist in Combination with a P2Y12 ADP Receptor Antagonist for Inhibition of Thrombosis"
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
WO2012109406A1 (fr) * 2011-02-09 2012-08-16 The Medicines Company Méthodes de traitement de l'hypertension pulmonaire
BR112014016764A8 (pt) * 2012-01-04 2017-07-04 The Medicines Co métodos de bloqueio de ativação de plaqueta durante circulação extracorpórea usando cangrelor
CN103860459A (zh) * 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
MA41326A (fr) * 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation

Also Published As

Publication number Publication date
CN107206014A (zh) 2017-09-26
CA2971868C (fr) 2023-04-04
CA2971868A1 (fr) 2016-07-21
US20160296549A1 (en) 2016-10-13
KR102440847B1 (ko) 2022-09-06
RU2733409C2 (ru) 2020-10-01
CN115990138A (zh) 2023-04-21
KR20170103848A (ko) 2017-09-13
US9700575B2 (en) 2017-07-11
PE20221170A1 (es) 2022-07-25
RU2017127531A (ru) 2019-02-14
EP3244900A1 (fr) 2017-11-22
MX2017009289A (es) 2017-10-11
US20160199400A1 (en) 2016-07-14
PE20171246A1 (es) 2017-08-24
US10039780B2 (en) 2018-08-07
EP3244900A4 (fr) 2018-05-30
US9295687B1 (en) 2016-03-29
US9439921B2 (en) 2016-09-13
RU2017127531A3 (fr) 2019-02-14
CL2017001840A1 (es) 2017-12-29
WO2016114818A1 (fr) 2016-07-21
BR112017014996A2 (pt) 2018-03-20
US20170304345A1 (en) 2017-10-26
CO2017006958A2 (es) 2017-11-30

Similar Documents

Publication Publication Date Title
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
HK1248547A1 (zh) 包含替諾福韋和恩曲他濱的藥物製劑
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
IL275639A (en) Formulation for RNA administration
MA42303A (fr) Formulations pharmaceutiques
MA42196A (fr) Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
IL264880A (en) Preparations for oral administration of active substances
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
BR112017009510A2 (pt) composições compreendendo ciclosporina
MA55015A (fr) Formulations pharmaceutiques
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
MA47141A (fr) Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
EP3389602A4 (fr) Compositions de soin buccal comprenant au moins un copolymère d'acrylate/phosphate et au moins un principe actif cationique
EP3506947A4 (fr) Formulations pharmaceutiques de régadénosone
EP3497080A4 (fr) Formulations pharmaceutiques et leur utilisation
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use